Abstract

For MDMA-assisted therapy for PTSD, training therapists is the key to positive treatment outcomes, and also to and to scaling the number of therapist necessary to meet the needs of millions of PTSD patients. I’ll discuss the elements of our treatment method and our therapist training program, including the importance of therapist having their own experience with MDMA in a therapeutic setting. I’ll discuss our negotiations with FDA regarding therapist credentials and a protocol for which therapist can volunteer to legally receive an MDMA session. I’ll discus the blending of MDMA with other modalities for the treatment of PTSD that MAPS is funding, along with a new study into group therapy for PTSD. I’ll discuss our drug development plans for Europe along with cost effectiveness and other data we will need to obtain national health care insurance coverage for this treatment throughout Europe.